{"id":5704,"date":"2024-05-02T09:19:26","date_gmt":"2024-05-02T14:19:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5704"},"modified":"2025-06-27T11:18:38","modified_gmt":"2025-06-27T16:18:38","slug":"nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaciones en la reuni\u00f3n anual de ARVO"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a02 de mayo de 2024<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias g\u00e9nicas para enfermedades degenerativas de la retina, anunci\u00f3 hoy que su plataforma de terapia g\u00e9nica Multi-Characteristic Opsin (MCO) se presentar\u00e1 en seis presentaciones en el\u00a0Reuni\u00f3n anual de ARVO<\/a>, teniendo lugar\u00a05 al 9 de mayo de 2024<\/span>\u00a0en\u00a0seattle<\/span>. El equipo directivo estar\u00e1 presente en la conferencia y disponible para reunirse en el stand #4620 de Nanoscope Therapeutics.<\/p>\n

Los detalles de las presentaciones son los siguientes:<\/p>\n

T\u00edtulo de presentaci\u00f3n:<\/b>\u00a0An\u00e1lisis longitudinal BCVA de la terapia optogen\u00e9tica independiente de la mutaci\u00f3n MCO-010 en dosis bajas o altas para la retinosis pigmentaria: resultados de 12 meses de una fase\u00a02b<\/span>\/3 ensayo cl\u00ednico aleatorizado, controlado de forma simulada, enmascarado por el paciente y el evaluador (RESTORE)
N\u00famero de presentaci\u00f3n:<\/b>\u00a02137
Tipo de presentaci\u00f3n:\u00a0<\/b>Sesi\u00f3n de art\u00edculos
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Retinitis pigmentosa
Fecha de la sesi\u00f3n:<\/b>\u00a06 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a04:15 \u2013\u00a04:30 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0612 –\u00a0seattle<\/span>\u00a0Centro de Convenciones \u2013 Edificio Arco
Presentador:<\/b>\u00a0Allen C. Ho, MD, asesor m\u00e9dico jefe<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0Concordancia test-retest del test de agudeza visual de Friburgo en visi\u00f3n ultrabaja
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0A0223
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Evaluaci\u00f3n del desempe\u00f1o de baja visi\u00f3n
Fecha de la sesi\u00f3n:<\/b>\u00a07 de mayo de 2024<\/span>
Tiempo de sesi\u00f3n:<\/b>\u00a01:15 \u2013\u00a03:00 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de Exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Samuel Barone, MD, director m\u00e9dico<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0An\u00e1lisis longitudinal de BCVA de pacientes con enfermedad de Stargardt y degeneraci\u00f3n macular tratados con MCO-010, una terapia optogen\u00e9tica independiente de las mutaciones: resultados de 48 semanas de un ensayo cl\u00ednico de fase 2a (STARLIGHT)
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0094
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Oftalmolog\u00eda pedi\u00e1trica y enfermedades oculares hereditarias
Fecha de la sesi\u00f3n:<\/b>\u00a08 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a02:15 \u2013\u00a04:00 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de Exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Vinit B. Mahajan, MD, PhD, Profesor de Oftalmolog\u00eda en\u00a0Universidad Stanford<\/span><\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0La terapia g\u00e9nica con opsina multicaracter\u00edstica aten\u00faa la degeneraci\u00f3n de la retina y restaura la visi\u00f3n en modelos de rat\u00f3n con retinosis pigmentaria
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0293
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapias gen\u00e9ticas y celulares y otras terapias novedosas I
Fecha de la sesi\u00f3n:<\/b>\u00a08 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a02:15 \u2013\u00a04:00 p.m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de Exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Subrata Batabyal, PhD, Director, Desarrollo no cl\u00ednico<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0Caracterizaci\u00f3n de una opsina multicaracter\u00edstica activable por luz ambiental de banda ancha que respalda su rendimiento superior en la restauraci\u00f3n de la visi\u00f3n
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0924
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapias gen\u00e9ticas y celulares y otras terapias novedosas II
Fecha de la sesi\u00f3n:<\/b>\u00a09 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a08:00 \u2013\u00a09:45 a. m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de Exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Samarendra Mohanty, PhD, presidenta y directora cient\u00edfica<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0Eficacia in vivo de una nueva opsina multicaracter\u00edstica (MCO-010) en un modelo de rat\u00f3n con amaurosis cong\u00e9nita de Leber
N\u00famero de resumen\/p\u00f3ster:<\/b>\u00a0B0942
Tipo de sesi\u00f3n:\u00a0<\/b>Sesi\u00f3n de carteles
T\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Terapias gen\u00e9ticas y celulares y otras terapias novedosas II
Fecha de la sesi\u00f3n:<\/b>\u00a09 de mayo de 2024
Tiempo de sesi\u00f3n:<\/b>\u00a08:00 \u2013\u00a09:45 a. m. hora del Pac\u00edfico<\/span>
Ubicaci\u00f3n:<\/b>\u00a0Sala de Exposiciones \u2013\u00a0seattle<\/span>\u00a0centro de Convenciones
Presentador:<\/b>\u00a0Najam Sharif, PhD, DSc, vicepresidente de investigaci\u00f3n y desarrollo global<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0Fase de RESTAURACI\u00d3N\u00a02b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la degeneraci\u00f3n macular relacionada con la edad.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0May 2, 2024\u00a0 — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in six presentations at the\u00a0ARVO Annual Meeting, taking place\u00a0May 5-9, 2024\u00a0in\u00a0Seattle. The management team will be present at the conference and available to […]<\/p>\n","protected":false},"author":6,"featured_media":5705,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-02T14:19:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:18:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"2000\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting\",\"datePublished\":\"2024-05-02T14:19:26+00:00\",\"dateModified\":\"2025-06-27T16:18:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"datePublished\":\"2024-05-02T14:19:26+00:00\",\"dateModified\":\"2025-06-27T16:18:38+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/NSCOPE_ARVO_LI_2024._V2.jpg\",\"width\":2000,\"height\":2000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/05\\\/02\\\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia presentaciones en la reuni\u00f3n anual de ARVO - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-05-02T14:19:26+00:00","article_modified_time":"2025-06-27T16:18:38+00:00","og_image":[{"width":2000,"height":2000,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting","datePublished":"2024-05-02T14:19:26+00:00","dateModified":"2025-06-27T16:18:38+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/"},"wordCount":567,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","url":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/","name":"Nanoscope Therapeutics anuncia presentaciones en la reuni\u00f3n anual de ARVO - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","datePublished":"2024-05-02T14:19:26+00:00","dateModified":"2025-06-27T16:18:38+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","width":2000,"height":2000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/05\/02\/nanoscope-therapeutics-announces-presentations-at-the-arvo-annual-meeting-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5704"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5704\/revisions"}],"predecessor-version":[{"id":9047,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5704\/revisions\/9047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5705"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}